NkGen Biotech will present Troculeucel, its cryopreserved enhanced autologous natural killer cell therapy, at the BIOCHINA Global Forum in Seoul on 10 July 2026, according to the company.
Paul Y. Song, M.D., chairman and chief executive officer, is scheduled to speak on the therapy in the Cell & Gene Therapy Innovations and R&D Collaboration track on Friday, 10 July at 13:40–14:00 KST, which converts to 12:40–1:00 AM Eastern.
The company claims Troculeucel is being evaluated in a Phase 2 clinical trial for Alzheimer’s disease and intends to discuss development opportunities across other neurodegenerative diseases including amyotrophic lateral sclerosis, frontotemporal dementia and Parkinson’s disease.
NkGen also plans to address the regulatory environment in China, including frameworks in select free trade zones and potential collaborations with Chinese pharmaceutical firms and contract development and manufacturing organizations.
The BIOCHINA Global Forum runs 9–10 July 2026 and serves as a platform for international scientific exchange and partnering.
